Message from CEO

As a patient-centric healthcare company, Ferozsons Laboratories Limited is committed to providing innovative healthcare solutions and ensuring patient access to world-class diagnosis, treatment and cure. 2016 marked our 60th year of putting patients first and seeing every day as a new opportunity to earn their trust and our credibility.

Our portfolio of in-licensed products and leading branded generics help improve the quality of life of patients suffering from heart disease, diabetes, GI and liver diseases, and cancer.

In our efforts to address critical healthcare challenges, we have also partnered with some of the world’s leading healthcare companies, including Gilead Sciences, Inc. USA – a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Hepatitis B and C affects over 20 Million Pakistanis.

In the areas of cardiovascular and metabolic diseases, we not only produce some of the most highly prescribed products for Angina, Congestive Heart Failure (CHF), Diabetes, Hypertension and Obesity, we also work with our partners, the Boston Scientific Corporation, to equip Healthcare practitioners with complete solutions that extend beyond pharmaceuticals to include the most innovative medical devices.

Maternal and Neonatal Child Health represents another serious challenge to our public health system. Annually nearly 80,000 mothers and newborns lose their lives in Pakistan, largely from preventable complications.

Ferozsons invests significantly in medical and public education programs aimed at patient awareness and disease prevention. Our social investments in education and health also help create access for patients who are unable to afford treatment.

Please browse through our website and feel free to reach out to us should you have any comments, feedback or queries.

Osman Khalid Waheed.
CEO and Director

TOP